About 96,500 results
Regeneron Pharmaceuticals Suffers Worst Month in Two Years …
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by …
GLP-1 demand is going to remain higher than supply for ... - CNBC
Buy Rating Affirmed for AbCellera Biologics Amid Positive TCE …
Eli Lilly’s Kisunla Approval Spurs Buy Rating Amid Anticipated …
Structure Therapeutics Stock Could Rocket 87% Higher, According …
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs …
Eli Lilly's GLP-1 demand drives up stock price post Q1 results
BMO Capital Markets Focused on Expanding Healthcare Franchise
Analyst says these are the 'critical' next steps for Eli Lilly
- Some results have been removed